Podcast- Dr. Jeffrey Weitz, M.D. -@Cardio_KULeuven #VenousThromboembolism #Cardiology #Research Abelacimab for Preve...

Dr. Jeffrey Weitz, M.D. -@Cardio_KULeuven #VenousThromboembolism #Cardiology #Research Abelacimab for Prevention of Venous Thromboembolism

Link to Abstract- https://www.nejm.org/doi/full/10.1056/NEJMoa2105872?query=cardiology

Abstract-

BACKGROUND
The relevance of factor XI in postoperative venous thromboembolism etiology is unknown. Abelacimab is a monoclonal antibody that binds to factor XI and locks it in an inactive precursor state called the zymogen.

METHODS In this open-label, parallel-group study, 412 patients undergoing total knee arthroplasty were randomly assigned to one of three abelacimab (30 mg, 75 mg, or 150 mg) regimens administered postoperatively in a single intravenous dose or 40 mg of enoxaparin administered subcutaneously once daily. The major efficacy endpoint was venous thromboembolism, which was diagnosed by either obligatory venography of the operative leg or objective confirmation of symptomatic episodes. Up to 30 days following surgery, the primary safety outcome was a composite of major or clinically relevant nonmajor bleeding.

RESULTS
Venous thromboembolism occurred in 13 of 102 patients (13 percent), 5 of 99 patients (5 percent), and 4 of 98 patients (4 percent) in the 30-mg abelacimab group, compared to 22 of 101 patients (22 percent) in the enoxaparin group. The 30-mg abelacimab regimen was not inferior to enoxaparin, but the 75-mg and 150-mg abelacimab regimens were (P0.001). In the 30-mg, 75-mg, and 150-mg abelacimab groups, bleeding occurred in 2%, 2%, and none of the patients, respectively, and in the enoxaparin group, bleeding occurred in none of the patients.

CONCLUSIONS
Factor XI is critical for the development of postoperative venous thromboembolism, according to this study. After total knee arthroplasty, factor XI inhibition with a single intravenous dose of abelacimab was successful in preventing venous thromboembolism and was linked with a low risk of bleeding. (ANT-005 TKA EudraCT number, 2019-003756-37; Anthos Therapeutics; Anthos Therapeutics; Anthos Therapeutics; Anthos Therapeutics; Anthos Therapeutics; Anthos Therapeutics; Anthos Therapeutics; Anthos Therapeutics; Anthos Therapeutics; Anthos Therapeutics; Anthos Therapeutics; Anthos Therapeutics;